RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Oxford Biomedica Stocks 2024

Oxford Biomedica Stocks

96.56 M

Oxford Biomedica Dividend yield

Ticker

OXB.L

ISIN

GB00BDFBVT43

WKN

A2JLRX

In 2024, Oxford Biomedica had 96.56 M outstanding stocks, a 0% change from the 96.56 M stocks in the previous year.

The Oxford Biomedica Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
2027e96.56
2026e96.56
2025e96.56
2024e96.56
202396.56
202294.83
202185.64
202079.94
201972.71
201869.24
201761.91
201655.56
201551.4
201440.39
201328.32
201222.93
201118.7
201010.88
200911.42
200811.33
200711.14
200610.55
20058.04
20047.92

Oxford Biomedica Aktienanalyse

What does Oxford Biomedica do?

Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Oxford Biomedica's Shares Outstanding

Oxford Biomedica's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Oxford Biomedica’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Oxford Biomedica’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Oxford Biomedica’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Oxford Biomedica Stock

How many stocks are there of Oxford Biomedica?

The current number of stocks of Oxford Biomedica is 96.56 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Oxford Biomedica are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Oxford Biomedica evolved in recent years?

The number of shares of Oxford Biomedica has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Oxford Biomedica as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Oxford Biomedica?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Oxford Biomedica pay?

Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.

What is the dividend yield of Oxford Biomedica?

The current dividend yield of Oxford Biomedica is .

When does Oxford Biomedica pay dividends?

Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oxford Biomedica?

Oxford Biomedica paid dividends every year for the past 0 years.

What is the dividend of Oxford Biomedica?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oxford Biomedica located?

Oxford Biomedica is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oxford Biomedica from 5/26/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/26/2024.

When did Oxford Biomedica pay the last dividend?

The last dividend was paid out on 5/26/2024.

What was the dividend of Oxford Biomedica in the year 2023?

In the year 2023, Oxford Biomedica distributed 0 GBP as dividends.

In which currency does Oxford Biomedica pay out the dividend?

The dividends of Oxford Biomedica are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Oxford Biomedica stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Oxford Biomedica

Our stock analysis for Oxford Biomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxford Biomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.